Ascentage Pharma Group International
NASDAQ:AAPGBiotechnology
+$0.31 today
- Market cap
- $1.21B
- Beta
- 0.65
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$13.29
Volume 0.00M
Average 0.01M
AAPG Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Ascentage Pharma Group InternationalNASDAQ: AAPG
Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025
Cost of revenue grows 389.7% year over year
Q4 FY2025 cost of revenue of CN¥68.69M rose 389.7% year over year. Over 3 fiscal years it compounded at +81.6% a year.
Context
- Cost of revenue amounted to 23.6% of revenue in FY2025, up 20.6 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
CNY · from the income statement
- Latest · FY2025
- 131.73M CNY
- Year-over-year change
- +352.9%
- 4-year CAGR
- +150.8%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 131.73M | +352.9% |
| FY2024 | 2024-12-31 | 29.09M | -4.8% |
| FY2023 | 2023-12-31 | 30.54M | +38.8% |
| FY2022 | 2022-12-31 | 22M | +561.0% |
| FY2021 | 2021-12-31 | 3.33M | — |
Cost of Revenue vs competitors
How AAPG compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +352.9% is the 2nd highest of 8, against a peer median of +21.7%.
- Cost of revenue amounts to 23.6% of revenue for AAPG, versus a peer median of 13.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $244.96M USD | +232.7% | +29.8% | 108.7% | |
| LTM Jun 2026 | $195.71M USD | +21.7% | +37.2% | 43.5% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥131.73M CNY | +352.9% | +81.6% | 23.6% |
| LTM Aug 2026 | $94.76M USD | -56.9% | -53.2% | 13.5% | |
| LTM Jun 2026 | $10.3M USD | -1.0% | — | 6.1% | |
| LTM Mar 2026 | $8.06M USD | — | — | 16.3% | |
| LTM Mar 2026 | $1.8M USD | -69.3% | — | 5.2% | |
| LTM Sep 2026 | $942K USD | +50.7% | — | — | |
| LTM Mar 2026 | $793.21K USD | +354.2% | +64.1% | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Jun 2024 | $0 USD | — | — | 0.0% | |
| Peer median (excluding AAPG) | — | +21.7% | +33.5% | 13.5% | |
Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.91M | 209.71M | 221.98M | 980.65M | 558.48M |
| Cost of Revenue | 3.33M | 22M | 30.54M | 29.09M | 131.73M |
| Gross Profit | 24.58M | 187.71M | 191.44M | 951.57M | 426.75M |
| Gross Margin | 88.1% | 89.5% | 86.2% | 97.0% | 76.4% |
| Research & Development | 766.49M | 743.1M | 706.97M | 947.25M | 1.08B |
| Selling, General & Admin | 191.26M | 328.02M | 376.46M | 383.12M | 522.67M |
| Operating Expenses | 957.75M | 1.04B | 1.06B | 1.32B | 1.61B |
| Depreciation & Amortization | 17.18M | 47.42M | 93.2M | 93.17M | 84.12M |
| EBITDA | (798.34M) | (786.97M) | (743.61M) | (237.63M) | (1.1B) |
| EBITDA Margin | -2860.4% | -375.3% | -335.0% | -24.2% | -196.1% |
| Operating Income | (869.84M) | (849.81M) | (872.64M) | (369.73M) | (1.18B) |
| Operating Margin | -3116.6% | -405.2% | -393.1% | -37.7% | -211.1% |
| Interest Income | 7.11M | 9.73M | 32.41M | 37.84M | 79.89M |
| Interest Expense | 16.73M | 52.79M | 96.06M | 64.46M | 52.6M |
| Other Income / Expenses | 37.59M | (37.36M) | (60.23M) | (25.53M) | (23.21M) |
| Income Before Tax | (832.25M) | (887.17M) | (932.86M) | (395.26M) | (1.2B) |
| Pre-Tax Margin | -2981.9% | -423.0% | -420.2% | -40.3% | -215.3% |
| Income Tax Expense | (49.83M) | (4.25M) | (7.15M) | 10.43M | 6.75M |
| Net Income | (782.42M) | (882.92M) | (925.64M) | (405.43M) | (1.21B) |
| Net Margin | -2803.4% | -421.0% | -417.0% | -41.3% | -216.5% |
| EPS (Basic) | (49.12) | (53.60) | (52.48) | (5.36) | (13.56) |
| EPS (Diluted) | (49.12) | (53.60) | (52.48) | (5.36) | (13.56) |
| Weighted Avg Shares | 15.91M | 16.48M | 17.64M | 75.52M | 89.03M |
| Weighted Avg Shares (Diluted) | 15.91M | 16.48M | 17.64M | 75.52M | 89.03M |
Ascentage Pharma Group International
NASDAQ:AAPG
Intrinsic Alpha fair value
Locked
Current Price
$13.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.